JP2005538046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538046A5 JP2005538046A5 JP2004500787A JP2004500787A JP2005538046A5 JP 2005538046 A5 JP2005538046 A5 JP 2005538046A5 JP 2004500787 A JP2004500787 A JP 2004500787A JP 2004500787 A JP2004500787 A JP 2004500787A JP 2005538046 A5 JP2005538046 A5 JP 2005538046A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- domain
- antibody
- monoclonal antibody
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037240 fusion proteins Human genes 0.000 claims 34
- 108020001507 fusion proteins Proteins 0.000 claims 34
- 102000002262 Thromboplastin Human genes 0.000 claims 11
- 108010000499 Thromboplastin Proteins 0.000 claims 11
- 102000012607 Thrombomodulin Human genes 0.000 claims 6
- 108010079274 Thrombomodulin Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000005614 monoclonal antibodies Human genes 0.000 claims 6
- 108010045030 monoclonal antibodies Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 4
- 101710044990 EGF3 Proteins 0.000 claims 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000002429 anti-coagulation Effects 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 230000028709 inflammatory response Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000001772 Blood Platelets Anatomy 0.000 claims 1
- 206010053567 Coagulopathy Diseases 0.000 claims 1
- 206010009802 Coagulopathy Diseases 0.000 claims 1
- 102000033147 ERVK-25 Human genes 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 229940012414 Factor VIIa Drugs 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 102000004851 Immunoglobulin G Human genes 0.000 claims 1
- 206010061256 Ischaemic stroke Diseases 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 108091005771 Peptidases Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 102100008880 TFPI Human genes 0.000 claims 1
- 101710034269 TFPI Proteins 0.000 claims 1
- 210000003462 Veins Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003197 catalytic Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003899 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000002209 hydrophobic Effects 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 230000001453 nonthrombogenic Effects 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 230000001732 thrombotic Effects 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Claims (29)
- トロンボモジュリン(TM)EGF456ドメイン又はその類似体、フラグメント、誘導体又は変異体に作用可能に結合された、組織因子(TF)又は第VII a因子/TF(FVII a/TF)複合体と相互作用する標的タンパク質を単独で、又はEGF3とEGF4との間のドメイン間ループ、EGF123ドメイン、O−結合されたグリコシル化ドメイン及びN−末端疎水性領域ドメイン、又はそれらの類似体、フラグメント、誘導体又は変異体から成る群から選択された少なくとも1つの追加のTMドメインと組合して含んで成る抗凝固融合タンパク質。
- 前記TMドメインが、EGF3とEGF4との間のドメイン間ループを含んで成る請求項1記載の融合タンパク質。
- 前記EDF456ドメインが、前記融合タンパク質を酸化損傷又はプロテアーゼ活性に対してより耐性にするか、又は前記融合タンパク質の触媒効率を高める点突然変異を含む請求項2記載の融合タンパク質。
- 前記EGF458ドメインが、H381G, M388L, R456G及びH457Qから成る群から選択された少なくとも1つの点突然変異を含む請求項3記載の融合タンパク質。
- 前記EGF456ドメインが、H381G, M388L, R456G及びH457Qから成る群から選択された少なくとも1つの点突然変異を含む請求項4記載の融合タンパク質。
- 前記標的タンパク質が、TFを結合する抗体である請求項1記載の融合タンパク質。
- 前記抗体がモノクローナル抗体である請求項6記載の融合タンパク質。
- 前記モノクローナル抗体が、TFのみに対してよりも高い親和性を用いてFVII a/TF複合体に結合する請求項7記載の融合タンパク質。
- 前記モノクローナル抗体が、一本鎖抗体、Fabダイマー抗体又はIgG抗体である請求項8記載の融合タンパク質。
- 前記モノクローナル抗体が、一本鎖抗体である請求項9記載の融合タンパク質。
- 前記モノクローナル抗体が、1よりも多くのTMドメインに作用可能に連結されている請求項7記載の融合タンパク質。
- 前記モノクローナル抗体が、TFを中和する請求項1記載の融合タンパク質。
- 前記融合タンパク質がグリコシル化されている請求項1記載の融合タンパク質。
- 前記融合タンパク質が、ポリエチレングリコールの添加により修飾されている請求項1記載の融合タンパク質。
- 前記融合タンパク質が、ストレプタビジンを結合するためにビオチニル化されている請求項1記載の融合タンパク質。
- 前記標的タンパク質がFVII aiである請求項1記載の融合タンパク質。
- 前記標的タンパク質がTFPIである請求項1記載の融合タンパク質。
- 治療的有効量の請求項1記載の融合タンパク質及び医薬的に許容できる賦形剤を含んで成る医薬組成物。
- 請求項1記載の融合タンパク質を含んで成る、他の凝固パラメーター、例えば血小板の活性化及び凝固に直接的に影響を及ぼさないで、血栓形成に対して保護する医薬組成物。
- 虚血性発作、血管形成に続く血栓合併症、又は微小血管手術における血栓形成に対して保護するための請求項19記載の医薬組成物。
- 請求項1記載の融合タンパク質を含んで成る、深静脈血栓症(DVT)、散在性血管内凝固(DIC)、急性冠状症候群、又は患者における凝固障害の現象を伴う癌を予防し、又は治療するための医薬組成物。
- 請求項1記載の融合タンパク質を含んで成る、炎症性応答を調節するための医薬組成物。
- 前記炎症性応答が、敗血症、皮膚及び静脈移植片、及び器官移植片から成る群から選択される請求項22記載の医薬組成物。
- 前記融合タンパク質が、血液と接触する医学用装置の表面上に非トロンボゲン性被膜を形成するために使用され得る請求項1記載の融合タンパク質。
- 請求項1記載の融合タンパク質を含んで成るキット。
- 請求項1記載の融合タンパク質成分をコードするDNA配列を含んで成るキット。
- 治療的有効量の遺伝子治療ベクターと共に、配列番号2又は3のアミノ酸配列から成る融合タンパク質をコードするDNAを含んで成る遺伝子療法組成物。
- H381G, M388L, R456G及びH457Qでの点突然変異から成るTM EGF456ドメイン及びEGF3とEGF4との間のドメイン間ループに作用可能に連結される、TF又はFVII a/TF複合体と相互作用する、TFを結合する一本鎖抗体である標的タンパク質を含んで成る抗凝固融合タンパク質。
- 前記融合タンパク質が、配列番号2又は3のアミノ酸配列を含んで成る請求項28記載の融合タンパク質。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37656602P | 2002-05-01 | 2002-05-01 | |
PCT/US2003/013522 WO2003092602A2 (en) | 2002-05-01 | 2003-04-30 | Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005538046A JP2005538046A (ja) | 2005-12-15 |
JP2005538046A5 true JP2005538046A5 (ja) | 2006-06-22 |
JP4567437B2 JP4567437B2 (ja) | 2010-10-20 |
Family
ID=29401364
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004500787A Expired - Fee Related JP4567437B2 (ja) | 2002-05-01 | 2003-04-30 | 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質 |
JP2004501558A Expired - Fee Related JP4460443B2 (ja) | 2002-05-01 | 2003-04-30 | 抗凝固剤としての新規組織因子標的化された抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501558A Expired - Fee Related JP4460443B2 (ja) | 2002-05-01 | 2003-04-30 | 抗凝固剤としての新規組織因子標的化された抗体 |
Country Status (29)
Country | Link |
---|---|
US (3) | US7250168B2 (ja) |
EP (2) | EP1549341B1 (ja) |
JP (2) | JP4567437B2 (ja) |
KR (2) | KR101080587B1 (ja) |
CN (2) | CN100563709C (ja) |
AR (1) | AR039515A1 (ja) |
AT (2) | ATE484524T1 (ja) |
AU (2) | AU2003225255B2 (ja) |
BR (2) | BR0304660A (ja) |
CA (2) | CA2483910A1 (ja) |
CR (1) | CR7584A (ja) |
DE (2) | DE60326970D1 (ja) |
DK (2) | DK1503785T3 (ja) |
EC (2) | ECSP045467A (ja) |
ES (2) | ES2354419T3 (ja) |
HK (1) | HK1080372A1 (ja) |
IL (3) | IL164733A0 (ja) |
MX (2) | MXPA04010851A (ja) |
NO (2) | NO20035849L (ja) |
NZ (2) | NZ536242A (ja) |
PE (1) | PE20040597A1 (ja) |
PL (2) | PL210582B1 (ja) |
PT (2) | PT1503785E (ja) |
RS (2) | RS102404A (ja) |
RU (2) | RU2345789C2 (ja) |
TW (1) | TWI343388B (ja) |
UA (2) | UA81114C2 (ja) |
WO (2) | WO2003092602A2 (ja) |
ZA (2) | ZA200409692B (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2135953B1 (en) | 1999-06-02 | 2014-04-23 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, Nr. 10 |
EP1221482B1 (en) * | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
EP2351855A1 (en) | 2000-09-26 | 2011-08-03 | Duke University | RNA aptamers and methods for identifying the same |
BR0304660A (pt) * | 2002-05-01 | 2005-06-07 | Schering Ag | Anticorpos direcionados a fator de tecido como anticoagulantes |
US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
CA2490280A1 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
US7425328B2 (en) | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
US7833978B2 (en) * | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
CN1980947B (zh) | 2004-04-22 | 2013-01-30 | 雷加多生物科学公司 | 改良的凝血因子调节物 |
JP4067557B2 (ja) * | 2005-06-03 | 2008-03-26 | 持田製薬株式会社 | 抗cd14抗体融合蛋白質 |
WO2008039206A2 (en) * | 2005-10-05 | 2008-04-03 | The Trustees Of The University Of Pennsylvania | Fusion proteins for inhibition and dissolution of coagulation |
CN101466400B (zh) * | 2006-04-07 | 2014-06-25 | 诺沃-诺迪斯克保健股份有限公司 | 共价凝血因子ⅶ-组织因子复合物 |
MY157796A (en) | 2006-06-08 | 2016-07-29 | Chugai Pharmaceutical Co Ltd | Preventive or remedy for inflammatory disease |
EP2062589A4 (en) * | 2006-10-06 | 2010-07-28 | Asahi Kasei Pharma Corp | THERAPEUTIC AND / OR ENHANCING AGENT FOR DISSEMINATED INTRAVASCULAR COAGULATION |
US9649499B2 (en) * | 2007-03-28 | 2017-05-16 | Medtronic ATS Medical, Inc. | Method for inhibiting platelet interaction with biomaterial surfaces |
US20100316563A1 (en) * | 2007-09-20 | 2010-12-16 | Bracco Imaging S.P.A. | Method For The Preparation Of New Oligoclonal Antibodies |
AU2008332276B2 (en) | 2007-12-05 | 2014-02-27 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
WO2009086552A1 (en) * | 2008-01-02 | 2009-07-09 | The Trustees Of The University Of Pennsylvania | Targeting recombinant therapeutics to circulating red blood cells |
UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
WO2010019493A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
WO2010045518A1 (en) * | 2008-10-16 | 2010-04-22 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
EP2230251A1 (en) * | 2009-03-19 | 2010-09-22 | Bracco Imaging S.p.A | Antibodies specifically active in the coronary plaque and method for their identification |
WO2011026000A1 (en) * | 2009-08-28 | 2011-03-03 | Bayer Healthcare Llc | Cofactors for thrombin activation of factor vii and uses thereof |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
CA2801223C (en) | 2010-06-04 | 2019-12-03 | Sk Chemicals Co., Ltd. | Fusion protein having factor vii activity |
EP3281956A3 (en) | 2010-06-15 | 2018-04-18 | Genmab A/S | Human antibody drug conjugates against tissue factor |
CA2807749C (en) | 2010-08-05 | 2023-02-28 | Council Of Scientific & Industrial Research | Protein fusion constructs possessing thrombolytic and anticoagulant properties |
RU2445365C1 (ru) * | 2010-11-03 | 2012-03-20 | Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") | Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты) |
BR112017022101A2 (ja) | 2015-04-14 | 2018-07-31 | Chugai Seiyaku Kabushiki Kaisha | An object for prevention and/or a medicine constituent for medical treatment of atopic dermatitis which contain IL-31 antagonist as an active ingredient |
WO2016176440A2 (en) * | 2015-04-28 | 2016-11-03 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as protein c activators |
WO2017189943A1 (en) * | 2016-04-28 | 2017-11-02 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant |
PE20190966A1 (es) * | 2016-11-16 | 2019-07-08 | Bayer Healthcare Llc | Factor viii direccionado a los globulos rojos y metodo para su uso |
BR102017005783A2 (pt) * | 2017-03-21 | 2018-10-02 | Fund Butantan | processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos |
JP2022513332A (ja) * | 2018-10-04 | 2022-02-07 | スロムボシス アンド コアグラシヨン アーべー | プロテインsレベルの決定方法 |
WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
CN114686444B (zh) * | 2020-12-31 | 2024-05-31 | 广州万孚生物技术股份有限公司 | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 |
CN114686443B (zh) * | 2020-12-31 | 2023-11-03 | 广州万孚生物技术股份有限公司 | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
ZA862768B (en) * | 1985-04-17 | 1986-12-30 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US5589173A (en) | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5437864A (en) * | 1987-03-31 | 1995-08-01 | The Scripps Research Institute | Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor |
US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
US4912207A (en) | 1987-05-06 | 1990-03-27 | Washington University | DNA clone of human thrombomodulin and portions thereof |
DK299087D0 (da) | 1987-06-12 | 1987-06-12 | Novo Industri As | Proteins and derivatives thereof |
US5298599A (en) * | 1988-12-30 | 1994-03-29 | Oklahoma Medical Research Foundation | Expression and purification of recombinant soluble tissue factor |
EP0458903A4 (en) * | 1989-02-17 | 1992-06-17 | Codon | Soluble analogs of thrombomodulin |
US5466668A (en) | 1989-04-28 | 1995-11-14 | Schering Aktiengesellschaft | Superior thrombomodulin analogs for pharmaceutical use |
US5256770A (en) * | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
US6063763A (en) | 1989-04-28 | 2000-05-16 | Schering Aktiengesellschaft | Protease-resistant thrombomodulin analogs |
KR930008093B1 (ko) | 1990-08-03 | 1993-08-25 | 아사히가세이고오교 가부시끼가이샤 | 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물 |
US5506134A (en) * | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
US5843442A (en) * | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
JPH0578397A (ja) * | 1991-01-29 | 1993-03-30 | Sumitomo Pharmaceut Co Ltd | 血栓溶解タンパク質 |
JPH06133780A (ja) * | 1992-10-23 | 1994-05-17 | Sumitomo Pharmaceut Co Ltd | 新規なt−PA改変体 |
US5916874A (en) | 1994-04-20 | 1999-06-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for treating liver injury |
US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
BR9909382A (pt) * | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
AU5081401A (en) * | 2000-03-16 | 2001-10-03 | Genentech Inc | Anti-tissue factor antibodies with enhanced anticoagulant potency |
US6632791B1 (en) | 2000-06-21 | 2003-10-14 | Schering Aktiengesellschaft | Thrombomodulin analogs for pharmaceutical use |
TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
EP1978108A3 (en) | 2002-01-08 | 2009-01-07 | Siemens Healthcare Diagnostics GmbH | Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |
BR0304660A (pt) * | 2002-05-01 | 2005-06-07 | Schering Ag | Anticorpos direcionados a fator de tecido como anticoagulantes |
US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
-
2003
- 2003-04-30 BR BR0304660-5A patent/BR0304660A/pt not_active IP Right Cessation
- 2003-04-30 UA UA20041109787A patent/UA81114C2/uk unknown
- 2003-04-30 KR KR1020047017458A patent/KR101080587B1/ko not_active IP Right Cessation
- 2003-04-30 MX MXPA04010851A patent/MXPA04010851A/es active IP Right Grant
- 2003-04-30 PL PL373960A patent/PL210582B1/pl not_active IP Right Cessation
- 2003-04-30 PT PT03721975T patent/PT1503785E/pt unknown
- 2003-04-30 PT PT03721974T patent/PT1549341E/pt unknown
- 2003-04-30 UA UA20041109788A patent/UA85996C2/ru unknown
- 2003-04-30 MX MXPA04010795A patent/MXPA04010795A/es active IP Right Grant
- 2003-04-30 CN CNB038157039A patent/CN100563709C/zh not_active Expired - Fee Related
- 2003-04-30 DK DK03721975.5T patent/DK1503785T3/da active
- 2003-04-30 TW TW092110159A patent/TWI343388B/zh not_active IP Right Cessation
- 2003-04-30 ES ES03721975T patent/ES2354419T3/es not_active Expired - Lifetime
- 2003-04-30 AR ARP030101529A patent/AR039515A1/es active IP Right Grant
- 2003-04-30 PL PL03373945A patent/PL373945A1/xx not_active Application Discontinuation
- 2003-04-30 WO PCT/US2003/013522 patent/WO2003092602A2/en active Application Filing
- 2003-04-30 CA CA002483910A patent/CA2483910A1/en not_active Abandoned
- 2003-04-30 CN CNB038157020A patent/CN100412090C/zh not_active Expired - Fee Related
- 2003-04-30 KR KR1020047017456A patent/KR101013697B1/ko not_active IP Right Cessation
- 2003-04-30 AT AT03721975T patent/ATE484524T1/de active
- 2003-04-30 WO PCT/US2003/013521 patent/WO2003093422A2/en active Application Filing
- 2003-04-30 IL IL16473303A patent/IL164733A0/xx unknown
- 2003-04-30 JP JP2004500787A patent/JP4567437B2/ja not_active Expired - Fee Related
- 2003-04-30 ES ES03721974T patent/ES2323056T3/es not_active Expired - Lifetime
- 2003-04-30 AU AU2003225255A patent/AU2003225255B2/en not_active Ceased
- 2003-04-30 EP EP03721974A patent/EP1549341B1/en not_active Expired - Lifetime
- 2003-04-30 RS YU102404A patent/RS102404A/sr unknown
- 2003-04-30 RU RU2004135306/13A patent/RU2345789C2/ru not_active IP Right Cessation
- 2003-04-30 JP JP2004501558A patent/JP4460443B2/ja not_active Expired - Fee Related
- 2003-04-30 CA CA002483909A patent/CA2483909A1/en not_active Abandoned
- 2003-04-30 RU RU2004135308/15A patent/RU2320366C2/ru not_active IP Right Cessation
- 2003-04-30 DK DK03721974T patent/DK1549341T3/da active
- 2003-04-30 BR BR0304659-1A patent/BR0304659A/pt not_active IP Right Cessation
- 2003-04-30 AU AU2003225256A patent/AU2003225256B2/en not_active Ceased
- 2003-04-30 US US10/427,805 patent/US7250168B2/en not_active Expired - Fee Related
- 2003-04-30 EP EP03721975A patent/EP1503785B1/en not_active Expired - Lifetime
- 2003-04-30 DE DE60326970T patent/DE60326970D1/de not_active Expired - Lifetime
- 2003-04-30 NZ NZ536242A patent/NZ536242A/en unknown
- 2003-04-30 RS YUP-1045/04A patent/RS104504A/sr unknown
- 2003-04-30 NZ NZ536243A patent/NZ536243A/en unknown
- 2003-04-30 DE DE60334538T patent/DE60334538D1/de not_active Expired - Lifetime
- 2003-04-30 PE PE2003000426A patent/PE20040597A1/es not_active Application Discontinuation
- 2003-04-30 AT AT03721974T patent/ATE427121T1/de active
- 2003-12-30 NO NO20035849A patent/NO20035849L/no not_active Application Discontinuation
- 2003-12-30 NO NO20035848A patent/NO20035848L/no not_active Application Discontinuation
-
2004
- 2004-10-20 IL IL164733A patent/IL164733A/en not_active IP Right Cessation
- 2004-10-20 IL IL16473204A patent/IL164732A0/xx unknown
- 2004-11-24 CR CR7584A patent/CR7584A/es not_active Application Discontinuation
- 2004-11-30 EC EC2004005467A patent/ECSP045467A/es unknown
- 2004-11-30 ZA ZA200409692A patent/ZA200409692B/xx unknown
- 2004-11-30 EC EC2004005468A patent/ECSP045468A/es unknown
- 2004-11-30 ZA ZA200409694A patent/ZA200409694B/en unknown
-
2006
- 2006-01-06 HK HK06100300.9A patent/HK1080372A1/zh unknown
-
2007
- 2007-06-21 US US11/766,160 patent/US7622122B2/en not_active Expired - Fee Related
- 2007-06-21 US US11/766,155 patent/US7622457B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005538046A5 (ja) | ||
RU2004135308A (ru) | Новые слитые белки тромбомодулина, обеспечивающие направленный перенос к тканевому фактору, в качестве антикоагулянтов | |
JP2005532045A5 (ja) | ||
Weitz | New anticoagulant drugs | |
Dulon et al. | Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases | |
Hirsh | Current anticoagulant therapy—unmet clinical needs | |
US7354585B2 (en) | Methods of treating coagulapathic or thrombotic disorders | |
US20030171553A1 (en) | Tumour necrosis factor binding ligands | |
Abumiya et al. | An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma | |
Waters et al. | Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein | |
US20090317390A1 (en) | Novel tissue factor targeted antibodies as anticoagulants | |
JP2003527861A5 (ja) | ||
AU2014301041A1 (en) | Combination therapy using a Factor XII inhibitor and a C1-Inhibitor | |
JP2010504336A5 (ja) | ||
CN110099927A (zh) | 对抗xi因子的新型抗体及其用途 | |
Van De Craen et al. | Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo | |
EP1343823B1 (en) | Antithrombotic von willebrand factor (vwf) collagen bridging blockers | |
JP2009528293A5 (ja) | ||
WO1994009034A1 (en) | Clot directed anticoagulant, process for making same and methods of use | |
Toschi et al. | Biochemistry and biology of hirudin | |
Barbasz et al. | The assembly and activation of kinin-forming systems on the surface of human U-937 macrophage-like cells | |
Carrell et al. | Structural mobility of antithrombin and its modulation by heparin | |
JP2009503009A (ja) | 抗血小板剤としての直接的および間接的エフェクター細胞プロテアーゼ受容体−1(epr−1)阻害剤 | |
Naessens et al. | Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition | |
Tseng et al. | The effect of human C-reactive protein on the cell-attachment activity of fibronectin and laminin |